NEW YORK (TheStreet) -- Shares of Guess? (GES) fell in after-hours action on Wednesday after the Los Angeles-based specialty retailer and designer posted an in-line adjusted profit for its fiscal fourth quarter but gave a below-consensus outlook.
Guess? said it sees earnings of 41 to 44 cents a share for its fiscal first quarter ending in April on revenue of $555 million to $570 million. The current estimate of analysts polled by Thomson Reuters is for a profit of 61 cents a share in the April quarter on revenue of $595.6 million.
The stock was last quoted at $41.70, down 5%, on volume of more than 220,000, according to Nasdaq.com. Based on a regular session close at $43.87, the shares were down 5% in the past year, and they'd pulled back even more since hitting a 52-week high of $51.53 in late November.
For the full year, Guess? forecast earnings of $3.30 to $3.50 a share on revenue of $2.72 billion to $2.82 billion with its operating margins improving as 2011 wears on to a range of 16.5% to 17% from the 10% level it sees in the first quarter.The company also said its board had declared its regular quarterly dividend of 20 cents a share, and approved a new buyback program to repurchase up to $250 million worth of its common stock. The new authorization includes $85 million left over from the previous buyback program.
DepoMedShares of DepoMed (DEPO) rose in late trades after the Menlo Park, Calif.-based drug developer said in a regulatory filing that it has reached a settlement agreement with Abbott Labs (ABT) with regard to Gralise, a once-daily treatment for postherpetic neuralgia. According to the Form 8-K filed Wednesday with the Securities and Exchange Commission, the settlement calls for the licensing agreement between the two companies for Gralise to be terminated and for DepoMed to receive a payment of $40 million this month. The rights to Gralise will also transition back to DepoMed as part of the deal and the company expects its own launch of the drug to occur by the end of the fourth quarter. DepoMed also said it plans to seek a co-promotion partner for the drug to help it penetrate the primary care market.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV